TRAVERE THERAPEUTICS, INC. Restructuring and Related Cost, Expected Cost Remaining
TRAVERE THERAPEUTICS, INC. (TVTX) had Restructuring and Related Cost, Expected Cost Remaining of $1.40 million as of 2017-09-30, per its 10-Q filed 2017-11-07.
Discontinued › Notes › Restructuring and Related Activities
us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 · last filed 2017-11-07
- 2017-09-30: Restructuring and Related Cost, Expected Cost Remaining $1.40M.
| Period end | Restructuring and Related Cost, Expected Cost Remaining |
|---|---|
| 2017-09-30 | $1.40M 10-Q · filed 2017-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |